How Large a Patient Set Must Be for Validation When Going for CE Mark Certification?

When a medical device is ready to be sold in Europe, manufacturers must acquire a CE Mark, which represents the minimum safety and quality standards set forth by the European Union. Additionally, before a product can obtain its CE Mark, the manufacturer will need to complete a clinical evaluation using a number of clinical trials to assess performance and safety of the device. Ultimately, the question of how many patients you should include in your clinical trial, for your device to achieve CE Mark, is an important one; however, there is no "one-size-fits-all" answer as how large of a patient population will be required varies by medical device type and use, as well as medical device classification, risk classification and clinical evaluation strategy. In this guide, we provide an overview of how regulators determine sample size requirements along with how other factors, such as device classification, regulatory requirements and clinical evaluation plan, will factor into how you will calculate the ideal patient sample size as well as establish the strategy to conduct the necessary validation studies. Therefore, whether you are developing a diagnostic, implantable or digital health device, or would like further understanding regarding the requirements for CE Mark, you will find this document to be helpful and beneficial. This article will help you understand exactly what goes into determining a compliant and scientifically sound patient sample size.

Why Patient Sample Size Matters in CE Mark Certification

One of the fundamental components of the CE Marking process is clinical validation. Clinical evidence is not discretionary but is compulsory for medium- to high-risk devices. The number of patients that are evaluated forms the base for the Clinical Evaluation Report (CER); hence, it affects:

1. Safety conclusions

2. Performance claims

3. The risk-benefit assessment

4. Acceptance from a regulatory authority

5. Time to receive market approval

The lack of clinical evidence has been identified as one of the primary reasons for non-acceptance or delayed acceptance of the CE Mark process. Manufacturers frequently seek out CE Mark Certification Services that include Clinical Evaluation planning; justification for patient sample sizes and protocols.

Understanding Regulatory Expectations for Sample Size

The size of the sample for clinical evaluation under the MDR does not have a specific value listed. Instead, the size must be justified by providing an appropriate scientific rationale supported by established statistical principles.

Regulatory bodies want that:

• The size is statistically significant

• The size reflects how the product will be used in actual clinical practice

• Sufficient data is generated to support the intended purpose claims of the medical device

• The sample is of sufficient size to enable a thorough assessment of risks associated with the device

• For high-risk devices, the sample should be large enough to evaluate the number of adverse events

Reference documents for determining the sample size include:

• EU Medical Device Regulation (2017) (EU MDR 2017/745)

• MEDDEV 2.7/1 Revision 4

• MDCG guidelines

• ISO 14155:2020 (Clinical Trial Good Clinical Practice (GCP) for medical devices)

On the other hand, these documents guide in the clinical evaluation process, but the ultimate decision on the number of patients to include in clinical trials should be based upon scientific reasoning. As such, instead of asking, “What does the EU require?” the question is more appropriately stated as: “How many patients should I have to provide appropriate data regarding the safety and effectiveness of my device?”

General Patient Set Size Expectations for Clinical Validation

While there are no strict regulations about how many patients are needed to support medical device testing, there are industry benchmarks that can help guide your device's development. Below are recommended patient ranges based upon risk class and device type:

1. Low-Risk Devices (Class I and Class IIa)

For low-risk devices that are either non-invasive or well established (i.e., have been on the market for a period of time). Patient set size: 20-60 patients based upon the following rationale:

• Less risk involved with the device and thus the performance of these devices is easier to assess.

• The clinical profile of the product carries a higher degree of safety.

• The best examples of low-risk devices include gait aids (e.g., walkers), thermometers for diagnostic purposes, and various types of mobility devices (e.g., wheelchairs).

In instances where the device is an equivalent to an existing device with a CE Mark, a smaller patient population will be required as long as sufficient data can demonstrate that equivalency has been proven.

2. Moderate-Risk Devices (Class IIb)

Moderate-risk devices, at their very best, involve semi-invasive functions. Patient set size: 60-150 patients based upon the following rationale:

• Moderate risk devices are those where several safety and performance endpoints must be validated.

• Some examples of moderate-risk devices would be infusion pumps, ventilator support devices, some diagnostic instruments.

Notified Bodies tend to expect strong datasets from manufacturers, including evidence that the results of the tests are reproducible.

3. High-Risk Devices (Class III)

High-risk devices are those that sustain or support human life; or are very high-risk therapeutic actions.

• Patients set size: 150-300+ patients with a rationale of being able to provide a comprehensive amount of clinical evidence over time with statistical power.

• Some examples of high-risk devices would include heart valves, pacemakers, and other implantable devices. Class III devices typically need to have:

• multi-center studies conducted,

• larger patient populations enrolled, and

• longer-term follow up (6-24 months depending on risk) performed following the end of the trial period.

Factors That Determine the Required Patient Sample Size

The patient set for validation depends on a combination of technical, clinical, and regulatory factors. Let’s break them down.

1. Device Classification

The higher the device risk class, the larger the sample size required.

Device Class	Level of Evidence Needed	Typical Sample Size Range
Class I (Low Risk)	Minimal clinical data or literature-based evidence	10–50 (sometimes none)
Class IIa	Moderate clinical evidence	30–100
Class IIb	Strong clinical evidence, safety endpoints	75–200
Class III (High Risk)	Comprehensive clinical investigation	150–500+ depending on risk profile

These numbers are not official but reflect real-world expectations from Notified Bodies and experienced CE Mark Certification Service providers.

2. Purpose and Claims

Your claims about the product's performance influence how many people you need to test the device with.

For example:

• Glucose monitors that states "All readings will be accurate within ±10%.” has a higher in value versus "This monitor allows you to track your blood glucose levels over time."

• A wound dressing used on chronic diabetic ulcers needs a higher in value compared to a dressing for acute (short term) soft tissue wounds.

More Claims = More Data

3. Complexity and Risk

For example, there are several different types of devices that have the potential for injury:

• Implantable devices

• Devices that monitor the heart

• Systems that use AI Diagnostics

• Devices combined with drugs

Regulators expect larger patient populations and may request post approval studies to confirm safety and efficacy.

4. Variability of Patients

Conditions that influence how they act:

• Age

• Gender

• Race

• How severe the condition is?

• Biological differences cause variability

Your study population must represent these groups, and the more variety in your patients the larger the n value.

5. Statistical Power

You must justify sample size using statistical equipment including:

• Power level (typically 80-90%),

• Confidence Level (95%),

• Expected effect size,

• Acceptance criteria, and

• Clinical standard deviation.

A properly powered study reduces the likelihood of inconclusive or rejected study findings.

6. Availability of Existing Clinical Data

As per EU MDR, notarized bodies expect manufacturers to demonstrate that their products have gone through the entire design and development process, including establishing the required clinical evidence. If there is already existing clinical data available (e.g. published literature, post-market surveillance or previous trials), it may reduce the required sample size; however, as discussed above, there will still be an expectation to provide device specific evidence, particularly with respect to high-risk devices.

Typical Sample Size Recommendations by Device Type

Although there is no single answer for every situation, the following ranges can be used as a general benchmark across the industry:

1.Diagnostic Devices

• 50–200 Patients

• For sensitivity/specificity testing larger sample sizes are needed

2. Wearable/Digital Health Devices

• 40–150 Patients

• For algorithmic devices additional diversity of data may be needed instead of sample count.

3. Implantable Devices

• 150–500+ Patients

• Also requires long-term follow-up

4. Therapeutic Delivery Systems

• 80–200 Patients depending on the risk of the drug and the mechanism of delivery

5. Surgical Instruments and Tools

• 20-100 Patients

• With less variability than diagnostic devices.

These ranges should be taken into account when developing a plan, along with the experience of CE Certification Consultants in India, many of whom have the knowledge of what regulatory authorities expect in terms of clinical evidence and what is actually going to happen in practice.

How to Justify the Patient Sample Size in CE Marking Documentation

It is more important to justify the size of your sample scientifically than to simply state its size. The following are ways you can justify your sample size:

1.Justify the size of your sample using detailed statistics.

The justification process should provide:

• Hypothesis

• Statistical Model

• Power Analysis

• Error Margins

• Assumptions regarding Variability

2. Tie your sample size to specific clinical endpoints.

Ensure that all clinical endpoints are sufficiently powered to demonstrate significance.

3. Use real-world evidence where applicable.

Examples include post-market surveillance data, usability studies, and observational evidence that support your justification for your sample size.

4. Refer to regulatory guidance.

Alignment with ISO 14155 or MEDDEV is highly valued by Notified Bodies.

5. Document the Assumptions you made; specifically, document:

• Expected performance levels

• Risk thresholds

• Variability considerations for patients

The more transparent your justification, the easier the pathway to approval.

Common Mistakes Manufacturers Make

1.An Extremely Small Sample Size

Having a sample size that is too small will get you rejected by a Notified Body very quickly.

2. Literature Review Has A Greater Impact Than It Actually Does

It is unlikely that sufficient literature will be found under the EU MDR to conclude anything without further investigation.

3. Statistically Invalid Sample

A sample's suitability cannot be assessed based only on sample size; statistical justification is required.

4. Omitting Patient-Specific Differences

Not including the effects of geographic and other environmental variables increases the risks of approval.

5. Cutting Corners by Reducing Sample Size to Save Money

Using a smaller sample size will likely result in having to repeat the study, thus costing more in the long run because of additional costs incurred.

Role of CE Marking Certification Solutions and Consultants

To assist manufacturers with clinical validation strategy, many manufacturers utilize professional regulatory consulting teams. CE Certification Consultants are professionals who help manufacturers develop their clinical validation strategies by providing the following services:

• Development of Clinical Evaluation Plan

• Calculation of Sample Size

• Development of Clinical Protocol

• Performing a Risk-Benefit Analysis

• Collection of Real-World Evidence

• Drafting of CER

• Assistance and Communication with Notified Bodies

Manufacturers who work with experienced CE Certification Consultants in India will improve their marketing prospects by having more accurate information about their products, resulting in lower risk for delays associated with the EU MDR.

Why Working with CE Certification Consultants in India Helps Optimize Patient Set Size

To determine an appropriate sample size based on scientific reasoning is dependent on:

• Understanding systematically within the context and framework of what is required by the regulatory agency,

• Collaborating with statistical, clinical and regulatory experts about the study design,

• Obtaining conformity with respect to the Medical Device Regulation (MDR) and

• Understanding the expectations of the Notified Body.

The assistance of experienced Medical Device CE Certification Consultants in India includes:

• Development of a Clinical Evaluation Plan (CEP),

• Provision of appropriate validation protocol design,

• Completion of Calculations that provide an estimate the Statistical Sample Size,

• Promotion of cost-effective recruitment of patients,

• Development of documents required by the Notified Body,

• Minimization of unnecessary increases to the required sample size,

• Provision of assurance the clinical evidence is compliant with the MDR.

Utilizing the assistance of experienced consultants will help to minimize delays in securing approval of a Medical Device CE Certificate and ultimately increase the chances of securing first-time acceptance by the Notified Body.

How CE Marking Certification Solutions Support Clinical Validation

Comprehensive Professional CE Mark Certification Services include:

• Comprehensive guidance regarding the regulatory requirements,

• Planning for the clinical validation of all clinical data,

• Creating the Risk Management File,

• Preparing the Technical File, and

• Establishing the Post-Market Surveillance (PMS) program and PMCF development and reporting,

• Assistance during Notified Body Audits

Using the right CE Mark Certification Service will ensure that the clinical validation is not only sufficient to meet the regulatory requirement, but also aligns with the MD Regulation while being time-efficient and cost-effective.

Conclusion

To successfully achieve CE Mark Certification, selecting appropriate size for your clinical validation patient samples is essential. Although the Medical Devices Regulation does not have a specific number of patients listed under its guidance, the clinical sample size must meet the requirements of the following; it should have a scientific basis (e.g., testing methods), statistical validity, and it must correlate with the medical device's risk category and intended use. When developing a clinical validation study for a low-risk Class I Medical Device and/or Class III Implant, your evidence quality will have a larger impact on obtaining CE Mark Certification than the quantity of evidence provided. Consulting with CE Certification experts in India and following prescriptive CE Marking Certification Solutions can greatly expedite the process, keep you compliant with EU legal standards, and avoid delays due to noncompliance. Comprehensive, complete, and properly documented Clinical Validation Studies can improve your chances of successfully acquiring your CE Mark and launching your medical device into the European market.